Bal Pharma Limited (BALPHARMA) AI Stock Analysis

• Market Cap: ₹1.32B
• Dividend Yield: 1.45%
• Average Volume (3M): 4.30K
• Price to Earnings (P/E): 15.6
• Beta (1Y): 0.65
• Revenue Growth: -14.16%
• EPS Growth: 10.85%
• Country: IN
• Employees: 868
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.13
• Shares Outstanding: 15,920,872
• 10 Day Avg. Volume: 4,824
• 30 Day Avg. Volume: 4,299
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹92.00
• Price Target Upside: 11.18% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 60 Neutral
• Price Target: ₹92.00 ▲(11.18% Upside)

The overall stock score of 60 reflects moderate financial performance with stable gross margins but challenges in profitability and cash flow consistency. Technical indicators suggest bearish momentum, while valuation metrics indicate a fair market price. The absence of earnings call data and corporate events limits additional insights.

Bal Pharma Limited Business Overview & Revenue Model

Company Description

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.

How the Company Makes Money

Bal Pharma Limited generates revenue primarily through the sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's revenue streams include domestic sales of branded and generic formulations, as well as export sales to international markets. Bal Pharma's product portfolio spans across various therapeutic categories, allowing it to address diverse healthcare needs. Additionally, the company may engage in strategic partnerships and collaborations to expand its market reach and enhance its product offerings, contributing to its overall earnings.

Bal Pharma Limited Financial Statement Overview

Summary

Bal Pharma Limited demonstrates moderate growth with stable gross margins. However, it faces profitability challenges and high leverage, which could pose risks in downturns. Cash flow inconsistency further impacts financial stability, requiring improved cash management strategies.

Income Statement

Bal Pharma Limited shows moderate revenue growth over the years, with an increase from 2020 to 2024. The gross profit margin has been relatively stable, indicating decent cost management. However, the net profit margin is low, which suggests challenges in converting revenue into net income. The EBIT and EBITDA margins have seen fluctuations, reflecting operational efficiency issues.

Balance Sheet

The company's debt-to-equity ratio is high, indicating significant leverage which could pose risk if not managed well. ROE has improved annually, showing better returns on shareholder equity. The equity ratio is relatively low, suggesting a higher reliance on debt to finance assets.

Cash Flow

Operating cash flow has been inconsistent, with a significant drop in 2025 compared to previous years. Free cash flow has also faced volatility, turning negative in some years. The ratios of cash flows to net income indicate challenges in cash generation relative to earnings, potentially impacting liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.24B	3.03B	3.39B	3.04B	2.81B	2.51B
Gross Profit	1.13B	730.18M	770.20M	1.31B	1.11B	993.03M
EBITDA	347.10M	317.63M	320.23M	245.00M	287.64M	257.82M
Net Income	76.63M	72.15M	73.92M	25.72M	56.12M	47.42M
Balance Sheet
Total Assets	3.40B	3.36B	3.20B	3.13B	2.61B	2.40B
Cash, Cash Equivalents and Short-Term Investments	261.56M	105.19M	199.29M	90.81M	60.84M	39.71M
Total Debt	1.55B	1.50B	1.42B	1.31B	1.07B	1.12B
Total Liabilities	2.71B	2.58B	2.50B	2.49B	2.02B	1.87B
Stockholders Equity	687.92M	774.16M	692.94M	637.89M	586.27M	535.81M
Cash Flow
Free Cash Flow	59.25M	-145.55M	118.26M	-164.89M	192.39M	183.68M
Operating Cash Flow	59.25M	42.32M	228.06M	-18.43M	277.08M	217.81M
Investing Cash Flow	0.00	-156.53M	-188.91M	-221.82M	-94.85M	-49.80M
Financing Cash Flow	0.00	90.12M	-12.06M	244.00M	-181.34M	-166.32M

Bal Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 82.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALPHARMA, the sentiment is Negative. The current price of 82.75 is below the 20-day moving average (MA) of 86.65, below the 50-day MA of 90.21, and below the 200-day MA of 99.28, indicating a bearish trend. The MACD of -1.56 indicates Positive momentum. The RSI at 37.70 is Neutral, neither overbought nor oversold. The STOCH value of 22.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BALPHARMA.

Bal Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BAFNAPH	65 Neutral	₹4.14B	50.13	4.90%	―	2.36%	2924.94%
AAREYDRUGS	60 Neutral	₹2.23B	53.47	2.91%	―	-4.74%	-35.14%
BALPHARMA	60 Neutral	₹1.32B	15.58	―	1.45%	-14.16%	10.85%
MANGALAM	58 Neutral	₹1.14B	-11.69	4.51%	―	-16.39%	-410.09%
VAISHALI	55 Neutral	₹1.27B	385.95	1.26%	―	15.13%	-51.89%
KREBSBIO	44 Neutral	₹1.52B	-5.62	18.42%	―	-31.91%	-38.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%